Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
CNY 21.55
(-0.23%)
CNY 21.55
(-0.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 848.19 Million | 896.01 Million | 807.69 Million | 636.2 Million | 639.35 Million | 500.74 Million |
| Cost of Revenue | 40.18 Million | 41.27 Million | 34.43 Million | 28.53 Million | 22.85 Million | 28.51 Million |
| Gross Profit | 808 Million | 854.73 Million | 773.25 Million | 607.67 Million | 616.5 Million | 472.22 Million |
| Operating Expenses | 463.02 Million | 439.48 Million | 407.19 Million | 312.96 Million | 298.19 Million | 218.64 Million |
| Selling, General and Administrative Expenses | 332.43 Million | 317.38 Million | 290.79 Million | 231.15 Million | 231.83 Million | 177.12 Million |
| Research and Development Expenses | 38.19 Million | 106.01 Million | 87.92 Million | 64.87 Million | 41.17 Million | 13.47 Million |
| Other Expenses | 92.39 Million | 16.07 Million | 28.47 Million | 16.93 Million | 25.18 Million | 1.62 Million |
| Cost and Expenses | 503.21 Million | 480.76 Million | 441.62 Million | 341.5 Million | 321.04 Million | 247.16 Million |
| Operating Income | 344.97 Million | 396.2 Million | 392.9 Million | 321.51 Million | 343.37 Million | 271.35 Million |
| Interest Expense | 1.47 Million | 443.98 Thousand | 362.21 Thousand | 99.79 Thousand | 88.39 Thousand | 11.17 Million |
| Income Tax Expense | 50.43 Million | 63.02 Million | 66.7 Million | 52.89 Million | 53.09 Million | 41.11 Million |
| Earnings before Tax | 345.95 Million | 398.74 Million | 392.99 Million | 322.61 Million | 345.71 Million | 272.98 Million |
| Net Income | 310.18 Million | 348.77 Million | 337.99 Million | 278.44 Million | 298.29 Million | 232.88 Million |
| Earnings Per Share Basic | 0.59 | 0.67 | 0.65 | 0.53 | 0.57 | 0.44 |
| Earnings Per Share Diluted | 0.59 | 0.67 | 0.65 | 0.53 | 0.57 | 0.44 |
| Weighted Average Shares Outstanding | 523.6 Million | 523.58 Million | 523.58 Million | 523.58 Million | 523.58 Million | 523.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 523.6 Million | 523.58 Million | 523.58 Million | 523.58 Million | 523.58 Million | 523.57 Million |
| Gross Margin | 0.95 | 0.95 | 0.96 | 0.96 | 0.96 | 0.94 |
| EBIT Margin | 0.46 | 0.53 | 0.52 | 0.48 | 0.52 | 0.52 |
| Profit Margin | 0.37 | 0.39 | 0.42 | 0.44 | 0.47 | 0.47 |
| EBITDA | 391.09 Million | 425.27 Million | 422.41 Million | 339.17 Million | 328.66 Million | 260.83 Million |
| Earnings Before Tax Margin | 0.41 | 0.44 | 0.49 | 0.51 | 0.54 | 0.54 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 300.98 Million | 210.79 Million | 214.95 Million | 174.39 Million | 848.19 Million | 287.49 Million |
| Cost of Revenue | 12.94 Million | 20.97 Million | 10.41 Million | 9.22 Million | 40.18 Million | 11.48 Million |
| Gross Profit | 288.03 Million | 189.82 Million | 204.54 Million | 165.17 Million | 808 Million | 276.01 Million |
| Operating Expenses | 154.81 Million | 119.24 Million | 129.86 Million | 132.55 Million | 494.18 Million | 138.78 Million |
| Selling, General and Administrative Expenses | 225.59 Million | 94.91 Million | 99.3 Million | 49.17 Million | - | 132.07 Million |
| Research and Development Expenses | 28.6 Million | 24.33 Million | 30.56 Million | 33.7 Million | - | 28.9 Million |
| Other Expenses | -99.38 Million | -1.72 Million | -209.97 Thousand | 107.78 Thousand | 982.14 Thousand | -13.73 Thousand |
| Cost and Expenses | 167.76 Million | 140.21 Million | 140.28 Million | 141.78 Million | 534.37 Million | 150.26 Million |
| Operating Income | 143.74 Million | 70.58 Million | 74.67 Million | 44.38 Million | 344.97 Million | 140.87 Million |
| Interest Expense | 280.15 Thousand | 300.16 Thousand | 319.26 Thousand | 392.7 Thousand | 1.3 Million | 257.13 Thousand |
| Income Tax Expense | 23.15 Million | 13.99 Million | 13.87 Million | 8.75 Million | 50.43 Million | 22.79 Million |
| Earnings before Tax | 143.02 Million | 83.31 Million | 88.23 Million | 44.49 Million | 345.95 Million | 140.86 Million |
| Net Income | 123.02 Million | 72.02 Million | 77.2 Million | 40.03 Million | 310.18 Million | 121.54 Million |
| Earnings Per Share Basic | 0.24 | 0.14 | 0.15 | 0.08 | - | 0.23 |
| Earnings Per Share Diluted | 0.24 | 0.14 | 0.15 | 0.08 | - | 0.23 |
| Weighted Average Shares Outstanding | 523.58 Million | 523.58 Million | 523.58 Million | 523.59 Million | 523.6 Million | 523.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 523.58 Million | 523.58 Million | 523.58 Million | 523.59 Million | 523.6 Million | 523.58 Million |
| Gross Margin | 0.96 | 0.90 | 0.95 | 0.95 | 0.95 | 0.96 |
| EBIT Margin | 0.48 | 0.40 | 0.42 | 0.23 | - | 0.50 |
| Profit Margin | 0.41 | 0.34 | 0.36 | 0.23 | 0.37 | 0.42 |
| EBITDA | 143.3 Million | 83.45 Million | 89.31 Million | 40.12 Million | - | 144.5 Million |
| Earnings Before Tax Margin | 0.48 | 0.33 | 0.35 | 0.25 | 0.41 | 0.49 |
ALG
CWBK
2670
1183
SLQT
4919